Looking for some insightWas just looking around to see how much an impact the Bedrocan sales are going to impact the next Q growth. The last document posted for revenues for Bedrocan was for the three months prior to April 30th, 2015. Since then there has been no documentation of their sales expect for this subsection within the last Q report of CGC:
Acquisition of subsidiaries (continued)
(b) Bedrocan acquisition (continued)
Included in the Net Income for the year is a profit of $724,255 attributable to the Bedrocan Canada Inc.
acquisition since August 28, 2015. This amount included $1,692,661 of unrealized gain on changes in
fair value of biological assets and revenues of $347,006.
Had the business combination been effected at April 1
st, 2015, the revenue of the Company would
have increased by $1,120,321 and the Net Income for the year to date would have been reduced by
$1,552,017 including an unrealized gain on changes in fair value of biological assets.
Additional purchase consideration includes replacement options offered to employees and directors of
Bedrocan Canada Inc. The calculation of the amount to be recognized as purchase consideration is
not complete as of the date of the finalization of these condensed consolidated financial statements. It
is anticipated that this additional consideration will increase goodwill.
From what I understand, they are indicating that from August 28th until Sept 30th Bedrocan's sales were $724,255? If I am correct on interpreting this statement, that means we could see at least a 1.5 M revenue increase assuming there is not much growth in sales by BED since Sept. Can someone please shed some insight on this for me?